The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma
Journal of Gastroenterology · 2024
DOI: 10.1007/s00535-024-02144-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2024. Verfasst von Chengxiao Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Genome-Wide Association Study. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Jiangsu Funding Program for Excellent Postdoctoral Talent.
Abstract (Originalsprache)
BACKGROUND: Recent genome-wide association studies (GWASs) in liver diseases have generated some polygenic risk scores (PRSs), but their predictive effectiveness on hepatocellular carcinoma (HCC) risk assessment remains unclear. METHODS: Here, we constructed a novel combined polygenic risk score and evaluated its increment to the well-established risk model. We used 15 HCC-associated genetic loci from two PRSs and FinnGen GWAS data to calculate a PRS-combined score and to fit the related PRS model in the UK Biobank cohort (N = 436,162). The PRS-combined score was further assessed for risk stratification for HCC integrating with the recommended clinical risk scores. RESULTS: The PRS-combined model achieved a better AUC (0.657) than that of PRS-HFC (0.637) and PRS-cirrhosis (0.645). The top 20% of the PRS-combined distribution had a 3.25 increased risk of HCC vs. the middle decile (45-55%). At the population level, the addition of PRS-combined to the CLivD score significantly increased the C-statistic (from 0.716 to 0.746) and provided a remarkable improvement in reclassification (NRI = 0.088) at the 10-year risk threshold of 0.2%. In clinic, additional assessment of PRS-combined would reclassify 34,647 intermediate-risk participants as high genetic risk, corresponding to an increase of 63.92% (62/97) of the HCC events classified at high risk using the Fibrosis-4 alone. CONCLUSIONS: The PRS may enhance HCC risk prediction effectiveness in the general population and refine risk stratification of the conventional clinical indicator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Management Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, People's Republic of China.
- Department of Health Management, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
- Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
- Research Unit of Prospective Cohort of Cardiovascular Diseases and Cancers, Chinese Academy of Medical Sciences, Beijing, 100142, People's Republic of China.
- Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China. songci@njmu.edu.cn.
ORCID-Profile: Ci Song
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- Science and Technology Young Scientific and Technological Talents Project of Jiangsu Province
- China Postdoctoral Science Foundation
- Natural Science Foundation of Jiangsu Higher Education Institutions
- Chinese Academy of Medical Sciences
Zitieren
APA
Yu, C., Tang, Y., Liu, M., Xu, X., Ge, X., Ma, H., Jin, G., Shen, H., Song, C., & Hu, Z. (2024). The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02144-5
Vancouver
Yu C, Tang Y, Liu M, Xu X, Ge X, Ma H, et al. The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma. Journal of Gastroenterology. 2024. doi:10.1007/s00535-024-02144-5
BibTeX
@article{Yu2024,
author = {Yu, Chengxiao and Tang, Yuchen and Liu, Maojie and Xu, Xin and Ge, Xinyuan and Ma, Hongxia and Jin, Guangfu and Shen, Hongbing and Song, Ci and Hu, Zhibin},
title = {The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma},
journal = {Journal of Gastroenterology},
year = {2024},
doi = {10.1007/s00535-024-02144-5}
}
EUVIMED